Bank of America
SRNE

Bank of America’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bank of America’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,900
Closed -$18K – 9019
2021
Q4 		$18K Buy
+3,900
New +$24.2K ﹤0.01% 7557

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Bank of America's SRNE Position: Q1 2023 in Review

Bank of America sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 2,987,772 shares — an estimated $2.65M sold.

Bank of America first reported a position in SRNE in Q4 2013 and held it in 36 quarters. The position peaked at $3.48M in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Bank of America reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Bank of America sold 2,987,772 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $2.65M.
  • Bank of America first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 36 quarters.
  • Bank of America's Sorrento Therapeutics, Inc. position peaked at $3.48M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.